Posted by Michael Wonder on 27 Oct 2023
FDA approves Genentech’s Vabysmo for the treatment of retinal vein occlusion
27 October 2023 - Approval is based on two Phase 3 studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept.
Genentech announced today that the US FDA has approved Vabysmo (faricimab-svoa) for the treatment of macular oedema following retinal vein occlusion.
